Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAM-CDIFF vaccine in adults at risk of C. difficile infection
NCT01230957Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2010
- Primary completion
- Nov 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ACAM-CDIFF in Clostridium difficile infection (CDI) (7 arms), sponsored by Sanofi. Primary endpoints: Safety profile in terms of solicited and unsolicited reactions and Serum antitoxin IgG concentrations to Clostridium difficile toxins A and B. Started Oct 2010; status: completed.
02
Drugs
ACAM-CDIFF
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01230957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01230957.